Breaking News Instant updates and real-time market news.

INCY

Incyte

$81.34

0.84 (1.04%)

, NVS

Novartis

$88.05

3.59 (4.25%)

13:52
05/24/19
05/24
13:52
05/24/19
13:52

Incyte announces FDA approves Jakafi for acute GVHD

Incyte Corporation confirmed that the U.S. Food and Drug Administration has approved Jakafi for the treatment of steroid-refractory acute graft-versus-host disease, or GVHD, in adult and pediatric patients 12 years and older. Jakafi is the first and only FDA-approved treatment for this indication, the company said. Jakafi will be made available to appropriate patients with steroid-refractory acute GVHD immediately. "Incyte is committed to supporting patients and removing barriers to access medicines," the company stated, noting that eligible patients in the U.S. who are prescribed Jakafi have access to a program offering patient support, including financial assistance and ongoing education and resources. Jakafi is also indicated for treatment of polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea as well as intermediate or high-risk myelofibrosis, including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults. Jakafi is marketed by Incyte in the United States and by Novartis (NVS) as Jakavi outside the United States.

INCY

Incyte

$81.34

0.84 (1.04%)

NVS

Novartis

$88.05

3.59 (4.25%)

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

INCY Incyte
$81.34

0.84 (1.04%)

05/03/19
LEHM
05/03/19
DOWNGRADE
Target $82
LEHM
Equal Weight
Incyte downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Incyte to Equal Weight from Overweight and lowered his price target for the shares to $82 from $90. With the stock up 27% year-to-date, the analyst does not see enough upside optionality from the company's graft-versus-host disease opportunity or its early-stage pipeline.
05/15/19
PIPR
05/15/19
NO CHANGE
Target $95
PIPR
Overweight
Incyte price target raised to $95 from $85 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target for Incyte to $95 from $85 and reiterates an Overweight rating on the shares. The analyst models a U.S. atopic dermatitis and vitiligo launch in 2021 and 2023, respectively, with combined global sales surpassing $1B by the late 2020s. Incyte is "fully capable" of launching topical Jakafi in these indications with a specialty sales force of a couple hundred people, Van Buren tells investors in a research note. Further, the analyst notes that a key opinion leader Piper hosted was "very bullish" on topical Jakafi. The doctor believes that the efficacy of topical Jakafi exceeds that of the currently available non-steroidals, says Van Buren.
05/20/19
FBCO
05/20/19
INITIATION
Target $75
FBCO
Neutral
Incyte initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Incyte with a Neutral rating and $75 price target. The analyst wants to see more clinical evidence and trial execution in the company's its pipeline following last year's failure of epacadostat before coming more positive on the stock.
05/21/19
05/21/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Uber (UBER) initiated with an Equal Weight at Consumer Edge and a Neutral at Susquehanna. 2. Incyte (INCY) initiated with a Neutral at Credit Suisse. 3. Hillenbrand (HI) initiated with a Neutral at DA Davidson. 4. Target Hospitality (TH) initiated with a Buy at Deutsche Bank. 5. Jack in the Box (JACK) reinstated with an Equal Weight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NVS Novartis
$88.05

3.59 (4.25%)

05/13/19
WELS
05/13/19
NO CHANGE
WELS
Lawsuit against Teva, others to hit generic drug stocks, says Wells Fargo
Wells Fargo analyst David Maris believes the lawsuit by 44 states against 20 generic drugmakers will weigh on generic drug stocks this week and remain an "overhang issue for some time." Actual penalties and damages are impossible to calculate, but could be material, Maris tells investors in a research note. The analyst spoke to the Connecticut attorney general's office this morning and learned they are preparing for trial in these cases. Language the attorney general has used, such as "unprecedented" and his desire to clawback all gains from collusion, should be indicative of the states' intent, Maris writes. He believes that for a sector that is generally highly levered, and with some companies named already facing an overhang from opioid litigation like Teva (TEVA), this is "especially unwelcome news."
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.

TODAY'S FREE FLY STORIES

EB

Eventbrite

$16.00

-0.41 (-2.50%)

07:22
06/17/19
06/17
07:22
06/17/19
07:22
Initiation
Eventbrite initiated  »

Eventbrite initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSTM

Verastem

$1.39

0.125 (9.88%)

07:22
06/17/19
06/17
07:22
06/17/19
07:22
Hot Stocks
Verastem presents Copiktra clinical data at EHA »

Verastem announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STL

Sterling Bancorp

$20.36

-0.01 (-0.05%)

07:21
06/17/19
06/17
07:21
06/17/19
07:21
Conference/Events
Sterling Bancorp management to meet with Sandler ONeill »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

TC

TuanChe

$2.96

0.065 (2.25%)

07:21
06/17/19
06/17
07:21
06/17/19
07:21
Hot Stocks
TuanChe announces up to $20M share repurchase program »

TuanChe announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$54.30

-0.01 (-0.02%)

, UNFI

United Natural Foods

$10.28

-0.51 (-4.73%)

07:20
06/17/19
06/17
07:20
06/17/19
07:20
Recommendations
Thor Industries, United Natural Foods analyst commentary  »

Citi lowers price targets…

THO

Thor Industries

$54.30

-0.01 (-0.02%)

UNFI

United Natural Foods

$10.28

-0.51 (-4.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

AYX

Alteryx

$104.23

2.08 (2.04%)

07:19
06/17/19
06/17
07:19
06/17/19
07:19
Recommendations
Alteryx analyst commentary  »

Alteryx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRCL

Stericycle

$45.24

-0.41 (-0.90%)

07:19
06/17/19
06/17
07:19
06/17/19
07:19
Conference/Events
Stericycle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 21

    Aug

BWEN

Broadwind Energy

$2.17

0.02 (0.93%)

07:18
06/17/19
06/17
07:18
06/17/19
07:18
Hot Stocks
Broadwind Energy announces $29M of new tower orders »

Broadwind Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.24

-0.37 (-4.30%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
Teva analyst commentary  »

Citi removes Teva from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REVG

REV Group

$12.99

-0.555 (-4.10%)

07:17
06/17/19
06/17
07:17
06/17/19
07:17
Recommendations
REV Group analyst commentary  »

REV Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIXX

Homology Medicines

$18.56

0.16 (0.87%)

07:16
06/17/19
06/17
07:16
06/17/19
07:16
Hot Stocks
Homology Medicines says single dose HMI-102 resulted in long-term PKU correction »

Homology Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$33.01

0.08 (0.24%)

07:15
06/17/19
06/17
07:15
06/17/19
07:15
Conference/Events
Synovus management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

, PFE

Pfizer

$42.75

0.24 (0.56%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Breaking Hot Stocks news story on Array BioPharma, Pfizer »

Array BioPharma up 59% to…

ARRY

Array BioPharma

$29.59

0.17 (0.58%)

PFE

Pfizer

$42.75

0.24 (0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 16

    Sep

ALNY

Alnylam

$70.04

-1.15 (-1.62%)

07:14
06/17/19
06/17
07:14
06/17/19
07:14
Hot Stocks
Alnylam announces lumasiran results, full patient enrollment in ILLUMINATE-A, »

Alnylam announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$11.35

-0.31 (-2.66%)

07:13
06/17/19
06/17
07:13
06/17/19
07:13
Initiation
Amicus initiated  »

Amicus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 16

    Sep

PLX

Protalix

$0.42

-0.017 (-3.89%)

07:13
06/17/19
06/17
07:13
06/17/19
07:13
Hot Stocks
Protalix completes enrollment in Phase III Bright clinical trial of PRX-102 »

Protalix BioTherapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROP

Roper Technologies

$364.63

-0.43 (-0.12%)

07:12
06/17/19
06/17
07:12
06/17/19
07:12
Conference/Events
Roper Technologies management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 20

    Jun

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

07:12
06/17/19
06/17
07:12
06/17/19
07:12
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RWLK

ReWalk Robotics

$5.21

-0.215 (-3.97%)

07:11
06/17/19
06/17
07:11
06/17/19
07:11
Upgrade
ReWalk Robotics rating change  »

ReWalk Robotics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORGS

Orgenesis

$4.21

-0.09 (-2.09%)

07:11
06/17/19
06/17
07:11
06/17/19
07:11
Hot Stocks
Orgenesis gets Orphan Drug designation for Autologous Insulin Producing cells »

Orgenesis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBMG

Cellular Biomedicine

$14.68

-0.62 (-4.05%)

07:09
06/17/19
06/17
07:09
06/17/19
07:09
Hot Stocks
Cellular Biomedicine: First patient dosed in Phase 1 trial of anti-CD20 CAR-T »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$14.10

0.06 (0.43%)

07:08
06/17/19
06/17
07:08
06/17/19
07:08
Hot Stocks
Universal Stainless & Alloy reports fire at North Jackson, Ohio facility »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$8.24

-0.37 (-4.30%)

07:08
06/17/19
06/17
07:08
06/17/19
07:08
Recommendations
Teva analyst commentary  »

Teva price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$117.48

-7.52 (-6.02%)

, CELG

Celgene

$96.49

0.07 (0.07%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Hot Stocks
BeiGene, Celgene to terminate global collaboration for tislelizumab »

BeiGene (BGNE) announced…

BGNE

BeiGene

$117.48

-7.52 (-6.02%)

CELG

Celgene

$96.49

0.07 (0.07%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 27

    Jun

  • 25

    Jul

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

TWIN

Twin Disc

$14.02

0.125 (0.90%)

07:06
06/17/19
06/17
07:06
06/17/19
07:06
Hot Stocks
Twin Disc names James Feiertag as president and COO, effective May 1 »

Twin Disc has appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.